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SUMMARY 
Renal cell carcinomas with chromosome translocation are rare neoplasms which 
often occur in young patients. In the last World Health Organization (WHO 2016) 
are named as MiT family translocation renal cell carcinoma comprising two 
different entities: Xp11 renal cell carcinoma and t(6;11) renal cell carcinoma. 
Recently, renal cell carcinomas with TFEB amplification has been described in 
connection with t(6;11) renal cell carcinoma. We analyzed 30 MiT family 
translocation renal cell carcinoma and 2 renal cell carcinomas with TFEB 
amplification collecting data on clinical, histological, immunohistochemical and 
molecular features. In this study, we sought 1) immunohistochemical diagnostic 
markers (cathepsin K, CD68 (PG-M1), PAX8) since the differential diagnosis is 
challenging, especially with pure epithelioid PEComa/epithelioid 
angiomyolipoma; 2) fluorescence in situ hybridization diagnostic features to reach 
the correct diagnosis; 3) predictive markers (MET, AXL, VEGF) in tumor tissue 
for target therapy. Histologically, either cytological or architectural appearance 
was peculiar in each case. By immunohistochemistry, almost all MiT family 
translocation renal cell carcinomas expressed PAX8. Staining for cathepsin K was 
found in 65% of Xp11 renal cell carcinomas, only a few cases were positive for 
melanogenic markers and all cases were negative for CD68 (PG-M1 clone). All 
t(6;11) renal cell carcinomas labelled for cathepsin K and Melan-A and negative 
for CD68 (PG-M1 clone). Seven pure epithelioid PEComa /epithelioid 
angiomyolipomas, used as control, were positive for cathepsin K, melanocytic 
markers and CD68 (PG-M1) and negative for PAX8. All MiT family translocation 
renal cell carcinomas were negative for AXL; 61% of Xp11 renal cell carcinomas 
and 5 of 7 t(6;11) renal cell carcinomas expressed MET. Fluorescence in situ 
hybridization results showed the presence of TFEB gene translocation in all 
t(6;11) renal cell carcinomas and TFE3 gene translocation in all Xp11 renal cell 
carcinoma with a high frequency of split fluorescent signals (mean 74% and 68% 
respectively). Among the eight t(6;11) renal cell carcinomas, one case displayed a 
high level of TFEB gene amplification and two showed increased TFEB gene 
copy number (3-4 copies of fluorescent signals) with a concomitant increased 
number of CEP6. Those three cases behaved aggressively. By FISH, VEGFA was 
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amplified in all three cases with TFEB amplification and increased VEGFA gene 
copy number was observed in the two aggressive cases t(6;11) renal cell 
carcinomas with an overlapping increased number of TFEB fluorescent signals. 
Overall, VEGFA mRNA expression was observed in 8 of 10 cases (80%); of these 
8 cases, three cases showed high level TFEB amplification, one case showed 
TFEB rearrangement with increased TFEB gene copy number, while four showed 
TFEB gene rearrangement without increased copy number. In conclusion, we 
report the high frequency of split signals by FISH in MiT family translocation 
renal cell carcinomas suggesting that 40% of split signals could be used as the 
proper cut-off to reach the correct diagnosis.  We demonstrate the usefulness of 
CD68 (PG-M1) immunohistochemical staining in distinguishing MiT family 
translocation renal cell carcinoma from pure epithelioid PEComa/epithelioid 
angiomyolipoma. Finally, VEGF, MET but not AXL may be potential predictive 
marker for targeted therapy in MiT family renal cell carcinomas. 
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INTRODUCTION 
The microphthalmia (MiT) family of transcription factors includes four 
distinctly genes: MITF, TFEB, TFE3, and TFEC. They share sequence homology 
in their DNA-contacting basic domains and in the transactivation domains. 
Additionally, these factors can heterodimerize with each other 
1
. They 
physiologically regulate cell growth, differentiation, and survival in several tissue 
types. Several distinct tumors are associated with the dysregulation of this gene 
family, including renal cell carcinoma, melanoma, alveolar soft part sarcoma, 
clear cell sarcoma, and perivascular epithelioid cell neoplasms (PEComas). The 
new category of MiT family translocation renal cell carcinoma has been included 
into the World Health Organization(WHO) classification in 2016 
2
. The MiT 
family renal cell carcinoma comprising two different entities: Xp11 translocation 
renal cell carcinoma harboring TFE3 gene fusions and t(6;11) renal cell carcinoma 
harboring a MALAT1-TFEB gene fusion.  
   
Xp11 translocation renal cell carcinoma  
Xp11 translocation renal cell carcinomas are a distinctive subtype of renal cell 
carcinoma characterized by several chromosomal translocations involving TFE3 
transcription factor gene. In these tumors, the TFE3 gene is fused by translocation 
to one of several other genes 
3-6
: 
 t(X;1) (p11.2; q21.2) gene PRCC 
 t (X;17) (p11.2; q25) gene ASPL  
 t(X;1) (p11.2; p34) gene SFPQ (PSF)  
 t(X;17) (p11.2; q23) gene CLTC 
 t(X;3) (p11.2; q21) gene PARP14 
 t(X;10) (11.2; q23) unknown gene 
 t(X;17) (p11.2; q21.33) gene LUC7L3 
 t(X;19) (p11.2; q13.3) gene KHSRP 
 t(X;17) (p11.2; p13) gene DVL2 
 t(X;22) (p11.2; q11.21) gene MED15 
 t(X;6) (p11.2; q25.3) gene ARIDB 
 t(X;5) (p11.2; q31.2) gene MATR3 
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 t(X;1) (p11.2; p31.1) gene FUBP1 
 inv (X) (p11.2; q12) gene NONO (p54nrb)  
 inv(X) (p11.2; p11.3) gene RBM10 
 inv(X)(p11.23;p11.23) il gene GRIPAP1 
 
The three most common Xp11 translocation renal cell carcinomas are those 
bearing the t(X;1)(p11.2;q21) which fuses the PRCC and TFE3 genes, the 
t(X;17)(p11.2;q25) which fuses the ASPL and TFE3 genes, and the 
t(X;1)(p11.2;p34) which fuses the SFPQ (PSF) and TFE3 genes. Of interest, 
either t(X;17) renal cell carcinoma or alveolar soft part sarcoma harbor the same 
ASPL-TFE3 fusion gene 
7
. However, the translocation is balanced in t(X;17) renal 
cell carcinoma and unbalanced in alveolar soft part sarcoma, which may 
contribute to the clinical and morphological differences. The function of chimeric 
TFE3 fusion proteins can also vary which may explain the different histologic 
features observed in this tumor entity of renal cell carcinoma.  
  
Clinical Features  
Xp11 renal cell carcinoma comprises 20–75% of childhood renal cell 
carcinoma and 1–4% of adult renal cell carcinoma with an average age of onset of 
50 years 
8
 .The incidence of Xp11 translocation renal cell carcinoma in adults may 
be underestimated, likely for the morphological overlap with more common adult 
renal cell carcinoma subtypes, such as clear cell and papillary renal cell 
carcinoma. Clinically, there is not a typical presenting features. As is common for 
other renal cell carcinomas, roughly one-third of tumors is asymptomatic, often 
accidentally discovered.  Prior exposure to cytotoxic chemotherapy has been 
reported as a risk factor 
9
.  
 
Pathologic Features  
Gross Findings  
There is no a specific macroscopic appearance of Xp11 translocation renal 
cell carcinoma. They usually present as solitary cortical masses characterized by 
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tan-yellow cut surfaces with foci of hemorrhage and necrosis and occasionally 
focal cystic degeneration.  
  
Microscopic Features  
Histologically, Xp11 translocation renal cell carcinomas are characterized 
by heterogeneous architectural and cytologic features mimicking almost all 
subtypes of renal cell carcinoma. The most distinctive histologic pattern is the 
presence of papillary architecture with epithelioid clear cells. However, different 
architectures have been reported such as solid, nested, trabecular, and microcystic 
pattern. Tumor cells are clear to eosinophilic with varying amounts of cytoplasm. 
The nuclei may show variability in size and are generally large with a prominent 
eosinophilic nucleoli (typically G3 by ISUP/WHO 2016). Psammoma bodies are 
often present. The wide spectrum of morphology reported in Xp11 translocation 
renal cell carcinomas emphasizes the need to consider these carcinomas in the 
differential diagnosis of unusual renal cell carcinomas occurring in both children 
and adults 
3
.   
 
Immunohistochemical features  
Like other subtypes of renal cell carcinoma, Xp11 translocation renal cell 
carcinoma are positive for PAX8. Vimentin and CK7 are typically negative. 
Staining for CD10 is generally reported. Occasionally, Xp11 translocation renal 
cell carcinoma may express melanogenic markers such as Melan-A and HMB45. 
Cathepsin K is overexpressed in a subset of Xp11 translocation renal cell 
carcinomas (approximately 60%). Interestingly, PRCC-TFE3 renal cell carcinoma 
is labelled more frequently for cathepsin K than ASPL-TFE3 renal cell carcinoma 
10, 11
. TFE3 immunostaining, initially considered as the most sensitive and specific 
marker, should be cautiously used due to the not infrequent false-positive and 
false negative results 
12
. For this reason, the identification of the TFE3 
rearrangement by FISH assays on formalin-fixed and paraffin-embedded tissue 
sections is currently the gold standard to reach the correct diagnosis 
12
. 
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Prognosis and Treatment  
The outcome of Xp11 translocation renal cell carcinoma is highly variable, 
with some patients surviving decades with indolent disease and others dying 
rapidly of progressive disease. Overall, Xp11 translocation renal cell carcinoma 
shows lymph node metastasis and has a worse prognosis than papillary renal cell 
carcinoma and similar prognosis with clear cell renal cell carcinoma 
13
. Several 
studies have demonstrated that Xp11 translocation renal cell carcinoma in 
children have a relatively indolent course, despite their often advanced stage at 
presentation. Among Xp11 translocation renal cell carcinoma, patients with 
ASPL-TFE3 fusion have a worse prognosis, but it is still unclear whether the 
fusion partner plays a prognostic role 
13, 14
.  
  The optimal therapy for the Xp11 translocation renal cell carcinoma 
remains to be determined. For localized tumors, including patients with positive 
regional lymph nodes, surgery is the treatment of choice. For patients with 
hematogenous metastases, the current options are immunotherapy, therapies 
targeting vascular endothelial growth factor receptor, and target therapies for 
MET signaling pathway 
15-18
.  Unfortunately, to date there is no data regarding 
predictive markers to choose the best therapy for the single patient.  
 
t(6;11) renal cell carcinoma  
T (6;11) renal cell carcinoma is an extremely rare variant and accounts for 
0.02% of all renal carcinomas. Although the initial description was in children 
19
, 
t(6,11) renal cell carcinoma may occur in adults in the age range of other renal 
cell carcinomas. The t(6;11) translocation fuses the gene for TFEB with Alpha 
(MALAT1), an untranslated gene of unknown function, resulting in 
overexpression of native TFEB.   
 
Clinical Features  
The t(6;11) renal cell carcinomas are less common than the Xp11 renal cell 
carcinomas; approximately 60 cases documented in the literature, the majority of 
which in children and adolescents. However, it has been demonstrated that these 
neoplasms can occur in adults as well. The mean age of presentation is 34 years, 
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with a wide reported range of 3-77years. The tumor is usually an incidental 
finding. Similar to Xp11 translocation renal cell carcinoma, a subset of cases has 
occurred in patients who have received cytotoxic chemotherapy for other reasons.  
 
Pathologic Features  
Gross Findings  
As  Xp11 translocation renal cell carcinoma, t(6;11) renal cell carcinoma 
does not have a distinctive gross appearance.   
 
Microscopic Features  
Histologically, t(6;11) renal cell carcinoma has been classically 
characterized by a distinctive biphasic morphology with larger epithelioid cells 
and smaller cells clustered around eosinophilic spheres formed by basement 
membrane material 
3
. However, several reports have shown a broad range of 
morphology in molecular confirmed t(6;11) renal cell carcinomas. Papillary and 
tubulocystic architectures, clear cell and oncocytoma-like features, diffuse 
hyalinization with thick-walled blood vessels are some of the unusual pathological 
features described 
3
. The wide spectrum of morphology results in several 
differential diagnoses including Xp11 translocation renal cell carcinoma, pure 
epithelioid PEComa /epithelioid angiomyolipoma, and other more common types 
of renal cell carcinoma 
20-22
.  Among them, pure epithelioid PEComa /epithelioid 
angiomyolipoma is the most challenging.  
 
Immunohistochemical features  
Immunohistochemically, most t(6;11) renal cell carcinomas express 
PAX8, supporting renal tubular differentiation and melanogenic markers, such as 
HMB-45 and Melan-A. Cathepsin K is overexpressed in almost all t(6;11) renal 
cell carcinomas
23, 24
. Staining for TFEB was considered highly sensitive and 
specific for this tumor. However, the results can be inconsistent among 
laboratories, mainly because of technical factors such as ﬁxation time and 
differences in the methods of antigen retrieval. Like Xp11 translocation renal cell 
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carcinomas, the identification of the rearrangement by FISH analysis is the gold 
standard for the diagnosis 
25
.  
 
Prognosis and Treatment  
Most instances of t(6;11) renal cell carcinoma have an indolent clinical 
course with a few published cases demonstrating aggressive behavior 
3
. There are 
no well-established prognostic markers to predict the biological behavior.  
The radical surgery remains the best therapeutic strategy. Because of the 
rarity of this tumor, no information regarding neoadjuvant or adjuvant therapies 
are available. Like Xp11 renal cell carcinoma, these neoplasms have demonstrated 
the capacity to recur late (up to 8 years after diagnosis), so long-term follow-up is 
important for these patients. 
 
Renal cell carcinoma with TFEB amplification   
More recently, renal cell carcinomas with TFEB amplification have been 
identified and appear to be associated with a more aggressive clinical course. 
TFEB amplification in renal cell carcinoma can occur independently of or 
in association with TFEB rearrangement. TFEB gene rearrangement via 
chromosome translocation or amplification causes intact TFEB overexpression 
and drives subsequent expression of immunohistochemical markers such as 
cathepsin K, Melan-A and HMB45 
23
.  However, TFEB amplified renal cell 
carcinomas differ from TFEB-translocation renal cell carcinomas in several ways 
26
. First, they typically occur in older patients (mean 65 years) compared to 
unamplified TFEB translocation RCC (mean age 31 years). Second, their 
morphology is usually high grade and less distinctive than the biphasic 
appearance of the typical TFEB-translocation renal cell carcinoma. Third, 
melanogenic marker expression is less consistent: while all cases have expressed 
Melan-A, only approximately 50% express cathepsin K and HMB45. Fourth, 
TFEB amplified renal cell carcinomas typically have an aggressive clinical course 
while TFEB-translocation renal cell carcinoma usually are indolent. 
TFEB gene is located in the short arm of chromosome 6, specifically in the 
6p21-p23 region, immediately adjacent to vascular endothelial growth factor A 
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(VEGFA) gene. Given the proximity of those two genes, it has been hypothesized 
and demonstrated that some renal cell carcinomas showing TFEB amplification 
harbor concurrent VEGFA amplification 
27
.   
 
 
MATERIAL AND METHODS 
Patients and samples 
Thirty MiT family translocation renal cell carcinomas and 2 TFEB-
amplified real cell carcinomas were retrieved from the files of University of 
Verona. The number of blocks from which hematoxylin eosin-stained sections 
were available for each tumor ranged from 1 to 41 (median 8). All slides were 
reviewed by two expert pathologists (AC, GM). For each case the following 
morphologic features were recorded: solid, nested, tubulocystic and papillary 
architecture, the presence of pseudocapsule, hyalinized stroma, necrosis and 
psammoma bodies. With respect to cellular features, the presence of small cells 
around the basement membrane, eosinophilic and clear cytoplasm, nucleolar grade 
according to ISUP/WHO 2016, and mitotic figures were assessed. 
 
Immunohistochemistry 
 Sections from tissue blocks of MiT family translocation renal cell 
carcinomas and TFEB amplified renal cell carcinomas were 
immunohistochemically stained with the following antibodies: PAX8 (clone 
BC12, DSB), Cathepsin K (clone 3F9, dilution 1:2000, Abcam), HMB45 (dilution 
1:30, Dako), Melan-A (clone A103, dilution 1:50, Novocastra), CD68 (clone PG-
M1, dilution 1:50, Dako and clone KP1, dilution 1:400, Dako) and cytokeratin 8-
18 (clone 5D3, dilution 1:100, Novocastra). To evaluate the possible predictive 
markers in tumor tissue, all 30 MiT family translocation renal cell carcinomas 
were immunohistochemically stained with MET (clone SP44, prediluted, 
Ventana), AXL (clone C89E7, dilution 1:100, Cell Signallig).  Seven pure 
epithelioid PEComa /epithelioid angiomyolipomas were immunohistochemically 
labeled with the same panel for comparison. All samples were processed using 
a sensitive “Bond Polymer Refine” detection system in an automated Bond 
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immunohistochemistry instrument (Leica Biosystems). The appropriate positive 
and negative controls were concurrently carried out. Labeling for each marker 
was recorded as the percentage of positive cells. With regards on the results of 
MET immunostaining, a grading of the intensity was also recorded by using a 
scoring scale based on three values: + (mild), ++ (intermediate) and +++ 
(strong). 
Fluorescence in situ hybridization (FISH) 
Fluorescence in situ hybridization (FISH) was carried out on the 32 tumors 
and the 37 control cases (10 clear cell renal cell carcinomas, 10 papillary renal cell 
carcinomas, 5 chromophobe renal cell carcinomas, 5 oncocytomas and 7 pure 
epithelioid PEComa /epithelioid angiomyolipomas) using dual color break apart 
TFE3 and TFEB probe (Cytotest Inc, Rockville, MD 20850, USA) and VEGFA 
(ZytoVision, Bremerhaven, Germany) probe. Centromeric alpha-satellite specific 
for chromosome 6 (CEP6) was used as control probes (Vysis-Abbott, Olympus, 
Rome, Italy) on serial tissue sections. Briefly, 3 µm sections were cut from 
formalin-fixed paraffin-embedded tissue blocks and mounted on positively 
charged slides. The slides were dried for one hour at 60°C then deparaffinized, 
rehydrated and fixed in methanol/acetic acid 3:1 for 5 min. Pretreatment was 
performed at 85°C for 30 min with 0,1 citrate buffer (pH6) solution followed by 
pepsin (4mg./ml in 0.9% NaCl, pH 1,5) treatment for 8 min at 37°C. After 
washing and dehydration, 10 µl probe was applied on selected area and sealed 
with rubber cement. Denaturation was assessed by incubating the slides at 80°C 
for 10 min in a humidified atmosphere (Thermobrite System) followed by 
hybridization overnight at 37°C. The rubber cement and the cover slip were 
removed and the slides were washed in 2X SSC/0,3% NP40 for 15 min at room 
temperature and then at 72°C for 2 min. Next, the tissue sections were 
counterstained with DAPI antifade (Prolong Gold Antifade Reagent Life 
Technologies) and examined under an X60- X100 oil immersion objective using 
an Olympus BX61 fluorescence microscope equipped with filters that visualize 
the different wavelengths of the fluorescent probe. 
Scoring was performed by two experienced pathologists (AC and MB). At 
least 100 neoplastic non-overlapping nuclei were included in the scoring. To 
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avoid false positive results due to nuclear truncation, cells with a single 
fluorescent signal were not evaluated. Ratio between mean copy number of TFEB 
gene / mean copy number of control centromeric probes CEP6 was ultimately 
scored. Amplification was defined by the presence of  >10 TFEB/VEGFA 
fluorescent signals or the LSI/CEP ratio was ≥2.  
 
mRNA in situ hybridization (RNAscope) 
The samples were analyzed with RNAscope assay (Advanced Cell 
Diagnostics, Newark CA USA) using RNAscope 2.5 HD Assay-Brown kit and 
the Probes-Hs-VEGFA. Ten renal tumors (3 clear cell renal cell carcinomas, 3 
papillary renal cell carcinomas, 2 chromophobe renal cell carcinomas, 2 
oncocytomas) were used as control cases. The procedure was performed manually 
following the manufacturer’s instructions. We used freshly cut 3µm. formalin-
fixed and paraffin-embedded slides dried for 1h at 60°C. The sections were 
deparaffinized and treated with the peroxidase block solution for 10 minutes at 
room temperature and then with retrieval solution for 15 minutes at 99°C. For 
each case 3 sections with targeted probes were incubated:  VEGFA, DAPB as 
negative control and UBC as positive control. The hybridization was performed 
for 2 h at 40°C. Slides were then washed and incubated with the signal 
amplification solution: amp1 for 30 minutes at 40°C, amp2 for 15 minutes at 
40°C, amp3 for 30 minutes at 40°C, amp4 for 15 minutes at 40°C, amp5 for 30 
minutes at room temperature, amp6 for 15 minutes at room temperature and 
finally with DAB for 10 minutes and hematoxylin  for the counterstaining. The 
results were examined under a standard bright-field microscope at X60 
magnification. Scoring was performed according to ACD guideline for semi-
quantitative assessment of RNAscope staining intensity as (0,1,2,3,4) 
(https://acdbio.com/technical-support/solutions). A positive result was considered 
when the neoplastic cells showed 3 or 4 intensity staining.  
 
Cytogenetic analysis 
Cells were cultured with in situ method (cover glass in a 35mm petri dish) 
and RPMI 1640 medium 20% FBS and harvested following standard cytogenetic 
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techniques. Briefly, each dish was examined daily after the fourth day for growth 
and the rate of proliferation. When cultures were ready the cells were exposed to 
colcemid (0.01 mg/ml) for 15 hours (overnight), hypotonic treatment (0.1% 
sodium citrate) and fixative solution (Carnoy). Karyotype was studied in QFQ 
banding (quinacrine dihydrochloride 500mg/100ml) by fluorescence microscopy. 
FISH was performed using TUPLE1 probe (Cytocell) following the manufacturer 
protocol. 
 
Statistical analysis 
Fisher's exact test was used to compare categorical data for clinical and 
pathological characteristics and Student’s t test to compare continuous data. All P 
values are based on a two-tailed hypothesis. The results were considered 
statistically significant if the P value was less than 0.05. 
 
 
RESULTS 
The results for Xp11 renal cell carcinomas and t(6;11) renal cell carcinomas were 
separately described for simplicity. 
 
Xp11 renal cell carcinoma 
 
Clinical features 
The clinical charateristics are detailed in Table 1.  Eleven patients were 
females and nine males (F:M ratio, 1:1,2).  The patients’ ages at diagnosis ranged 
from 10 to 75 years (mean 39, median 38). Patient 19 had a solid pseudopapillary 
tumor of the pancreas and the renal mass was an incidental finding. Follow up 
was available for thirteen patients, ranging from 6 to 132 months (mean 52, 
median 33). Three patients (patient 9, 13 and 16) were metastatic at the time of 
the diagnosis while one patient (patient 7) developed multiple peritoneal 
metastasis after 60 months from radical nephrectomy. Patient 16 began sunitinib 
for roughly one year with slight shrinkage of the renal mass. Because the 
remarkable progression on the liver metastases, nivolumab was initiated.   
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However, due to the frank progression on liver and bone metastases, the 
treatment was changed after two months. He received cabozantinib and died after 
two weeks from the beginning of the third line of treatment. Patient 13 is currently 
receiving sunitinib, and he is alive 4 months after the diagnosis with liver 
metastasis. 
Table 1. Clinical and pathological features of Xp11 renal cell carcinomas 
Case Age Gender Size/laterality Stage TNM Surgery Follow-up 
1 33 F 
n.a. n.a. n.a. 84 months alive 
2 75 F 4 cm/L pT1aNxMx 
Radical 
nephrectomy 24 months alive 
3 26 F 3 cm/n.a. pT1aNxMx 
Partial 
nephrectomy 12 months alive 
4 43 M 7 cm/L pT1bN1Mx 
Radical 
nephrectomy 
lymphnodes metastasis 
5 56 M 6,6 cm/R pT3aNxMx 
Radical 
nephrectomy 
n.a. 
6 31 M 10 cm/L pT2aNxMx 
Radical 
nephrectomy 
n.a. 
7 27 M n.a./R 
n.a. Radical 
nephrectomy 
multiple peritoneal 
 metastasis after 60 months 
8 29 M 
n.a. n.a. n.a. n.a. 
9 43 F 
1cm/L pT1aN1M1 Partial 
nephrectomy 
60 months alive with 
 supravicular lymph node 
metastasis 
10 70 F 7 cm/L pT1bNxMx 
n.a. 120 months alive 
11 39 F 6 cm/L pT1bN0M0 
Radical 
nephrectomy 
6 months alive 
12 
n.a. n.a. n.a. n.a. n.a. 
n.a. 
13 65 M n.a./R pT4N1M1 
Not performed 4 months alive with multiple  
hepatic metastasis  
14 16 M n.a./L 
n.a. n.a. 
120 months alive  
15 10 F n.a./R 
n.a. Radical 
nephrectomy 132 months alive 
16 25 M 6 cm/L pT1bN1M1 
 
Not performed 
dead after 17 months with 
bone, liver, abdominal and 
mediastinal lymph nodes 
metastases 
17 43 F 6,6 cm/L pT1bNxMx 
n.a. 33 months alive 
18 54 F 2,8 cm/L pT1aNxMx 
n.a. n.a. 
19 31 F 1,3 cm/R pT1aNxMx 
Partial 
nephrectomy 6 months alive 
20 
n.a. n.a. n.a. n.a. n.a. n.a. 
21 37 M 3,5 cm/R pT1aNxMx 
n.a. n.a. 
22 67 F 2,5 cm/R pT1aNxMx 
Partial 
nephrectomy n.a. 
F: female, M: male, R: right, L: left, n.a.: not available 
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Pathological features 
Twenty samples derived from the resection of the primary tumor (either 
radical or partial nephrectomy) two samples derived from lymph node metastasis 
(case 9) and renal biopsy (case 13) respectively.  The tumors ranged in size from 
1.3 to 10 cm (mean 5, median 6). The tumors were mainly solid with three cases 
multicystic. The morphological features are summarized in Table 2. The 
architectural patterns observed were papillary, tubular, cystic, alveolar, glandular, 
solid and nested, usually in combination. Necrosis was detected in 24% of the 
tumors, calcifications in 57%, and the presence of an incomplete pseudocapsule in 
43%. The tumor cells ranged in size from small to large with clear to granular 
eosinophilic cytoplasm. A biphasic architecture resembling the morphology of 
t(6;11) renal cell carcinoma was observed in one neoplasm (case 8). The most 
common nucleolar grade observed was G2 (48%), and G3 (48%) and only one 
case had a G1 score (4%) by ISUP/WHO 2016. 
Case 1 
The tumor showed pushing margins and made up of clear and eosinophilic 
polygonal cells with conspicuous nucleoli (G2 by ISUP/WHO 2016) arranged in 
solid/alveolar and psudopapillary architecture. Areas of hyalinized stroma,  
psammoma bodies, hemorrhagic areas and pigment bearing histiocytes were 
found (Figure 1f). No necrosis was observed. 
Case 2 and Case 3  
 The tumor was multicystic lined by a single layer of cells showing 
abundant vacuolated clear cytoplasm with round nuclei and pinpoint nucleoli (G2 
by ISUP/WHO 2016). Psammoma bodies were extensively present. Necrosis was 
absent. 
 
Case 4 
A discontinuous pseudocapsule was present. The neoplasm was mainly 
composed of large polygonal cells with well-defined cell borders, eosinophilic 
cytoplasm and central round nuclei with prominent nucleoli (G3 by ISUP/WHO 
2016) arranged in solid/alveolar and tubular-papillary architecture. 
Lymphovascular invasion, peritumoral inflammatory cells and a few psamomma 
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bodies were seen. Focal necrosis was present. Five of seven hilar lymph nodes 
examined were positive for tumor metastasis. 
Case 5 
The tumor was characterized by cells with clear to eosinophilic cytoplasm 
and small nuclei (G2 by ISUP/WHO 2016) arranged in papillary architecture and 
solid-alveolar pattern. A few psammoma bodies were found. 
Case 6 
The neoplasm was mainly composed of nests of polygonal cells with clear 
cytoplasm and central round nuclei with prominent nucleoli (G3 by ISUP/WHO 
2016) separated by thick fibrous tissue bundles. Additional areas showing cells 
with granular and eosinophilic cytoplasm were present. Tubular and papillary 
structures were also observed. Psammoma bodies and pigment bearing histiocytes 
were encountered. No necrosis was found. 
Case 7 
A discontinuous pseudocapsule was present. The neoplasm was mainly 
composed of cells with abundant eosinophilic cytoplasm and central round nuclei 
with prominent nucleoli (G3 by ISUP/WHO 2016) arranged in a solid alveolar 
pattern. Necrosis was present. 
Case 8 
 The tumor was partially made up of granular eosinophilic polygonal cells 
with conspicuous nucleoli (G2 by ISUP/WHO 2016) arranged in solid and 
tubular/alveolar architecture. At low power magnification, a biphasic population 
resembling the morphology of t(6;11) renal cell carcinoma were easily observed 
(Figure 2). At the periphery of the tumor, entrapped renal  normal tubules were 
focally present.  
Case 9 
Surgical sample of  lymph node metastasis was available for histological 
characterization and consisted of clear cells with distinct borders and small round 
nuclei (G2 by ISUP/WHO 2016) (Figure 2) with several psammoma bodies.  
Case 10 
The tumor was multicystic lined by a single layer of cells showing 
abundant vacuolated clear cytoplasm with round nuclei and pinpoint nucleoli (G1 
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by ISUP/WHO 2016) (Figure 1). Psammoma bodies were extensively present. 
Necrosis was absent. 
Case 11 
A discontinuous thick pseudocapsule was present. The tumor was 
composed of epithelioid cells with eosinophilic and focally clear cytoplasm and 
prominent nucleoli (G3 by ISUP/WHO 2016) mainly arranged in solid-tubular 
architecture. Neoplastic lymphovascular invasion and extensive necrosis were 
seen. Neither perirenal adipose tissue invasion nor renal sinus invasion was found. 
Case 12 
The tumor was well-delineated by a pseudocapsule. At low power 
magnification, papillary architecture made up of small cells with eosinophilic 
cytoplasm and round hypercromic nuclei (G2 by ISUP/WHO 2016) was observed. 
Additional areas mainly composed of clear cells with nuclear inclusions arranged 
in a solid-alveolar pattern were present (G2 by ISUP/WHO 2016). Several 
psammoma bodies were found throughout the tumor. 
Case 13 
The biopsy showed an epithelial neoplasm made up of sheets of small cells 
with round nuclei (G2 by ISUP/WHO 2016) and eosinophilic cytoplasm arranged 
in tubule-papillary architecture (Figure 2). No necrosis was observed.  
Case 14 
  A fibrous thick pseudocapsule with dystrophic calcification was present 
(Figure 1). The tumor was composed of epithelioid cells with clear cytoplasm and 
small nucleoli (G2 by ISUP/WHO 2016) mainly arranged in solid and papillary 
architecture. Areas with granular eosinophilic cells with prominent nucleoli (G3 
by ISUP/WHO 2016) were observed. Hyaline sclerosis was seen.  
Case 15 
The tumor was characterized by cells with eosinophilic cytoplasm and 
small nuclei (G2 by ISUP/WHO 2016) arranged in papillary pattern with 
psammoma bodies. 
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Case 16 
The tumor was solid and focal papillary composed of large epithelioid 
cells with eosinophilic to focally clear cytoplasm with prominent nucleoli (G3 by 
ISUP/WHO 2016). Areas of extensive tumoral necrosis was observed.   
Case 17 
  A discontinuous thick pseudocapsule was present. The tumor was 
composed of epithelioid cells with clear cytoplasm and small nucleoli (G2 by 
ISUP/WHO 2016) mainly arranged in solid-alveolar architecture. Areas with 
microcystic pattern and aggregates of histiocytes were seen. No necrosis was 
found. 
Case 18 
  A discontinuous thin pseudocapsule was present. The neoplasm was 
mainly composed of polygonal cells with eosinophilic to focally clear cytoplasm 
and central round nuclei with prominent nucleoli (G3 by ISUP/WHO 2016) 
arranged in a papillary architecture. Focally necrosis was encountered. 
Case 19 
The tumor showed a papillary architecture (Figure 1). The neoplastic cells 
were large and epithelioid with abundant clear cytoplasm and enlarged 
hyperchromatic nucleoli (G3 by ISUP/WHO 2016) (Figure 2). Histiocytes and 
psammoma bodies were present.  
Case 20: No information available. 
Case 21 
The tumor was well-delineated by a pseudocapsule. However, an 
infiltrative growth of the neoplastic cells through the pseudocapsule was 
frequently observed. At low power magnification, a mixture of tubular, papillary 
and microcystic patterns was seen. The neoplastic cells showed a clear cytoplasm 
and enlarged nucleoli (G3 by ISUP/WHO 2016). Several psammoma bodies were 
found. Necrosis was absent. 
Case 22 
  A discontinuous pseudocapsule was present. The tumor consisted of clear 
to focally eosinophilic cells with prominent nucleoli (G3 by ISUP/WHO 2016). 
Architecturally, tubular-glandular areas and papillary changes were observed.  
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No necrosis was observed.             
 
 
Figure 1. Different histologic appearances of Xp11 renal cell carcinoma. 
Neoplasm with papillary/tubular architecture composed by eosinophilic 
epithelioid cells (A, B) with psammoma bodies (B).  A multicystic tumor (C) 
lined by clear cells (D). The presence of a thick pseudocapsule is a common 
feature (E). Hyaline sclerosis may be observed (F). 
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Table 2 . Histological features of  Xp11 renal cell carcinoma 
Case Architecture Cellular features: size/staining ISUP grade Necrosis 
1 pseudopapillary/solid medium / clear and eosinophilic G2 absent 
2 multicystic medium / clear G2 absent 
3 multicystic medium / clear G2 absent 
4 solid-alveolar/papillary  large / eosinophilic G3 present 
5 solid-alveolar/papillary medium / clear and eosinophilic G2 absent 
6 nested/tubular-papillary medium / clear and eosinophilic G3 absent 
7 solid-alveolar large / eosinophilic G3 present 
8 biphasic: solid / tubular medium / eosinophilic G2 absent 
9 solid-alveolar medium / clear G2 absent 
10 multicystic medium / clear G1 absent 
11 solid/tubular large / eosinophilic G3 present 
12 solid-alveolar/papillary small / eosinophilic - medium / clear G2 absent 
13 papillary  small / eosinophilic G2 absent 
14 solid-alveolar/papillary medium / clear and eosinophilic G3 absent 
15 papillary small / eosinophilic G2 absent 
16 solid/papillary medium / clear and eosinophilic G3 present 
17 solid-alveolar/microcystic medium / clear G2 absent 
18 papillary medium / clear and eosinophilic G3 present 
19 papillary medium / clear and eosinophilic G3 absent 
20 n.a. n.a. n.a n.a 
21 tubular/papillary/microcystic medium / clear and eosinophilic G3 absent 
22 tubular/papillary medium / clear and eosinophilic G3 absent 
n.a.: not available 
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Figure 2. Different histologic appearances of Xp11 renal cell carcinoma. 
Biopsy sample showing tubular/papillary tumor composed by small eosinophilic 
cells (A). Lymph node metastasis of epithelial tumor with alveolar architecture 
made up of clear and eosinophilic cells (B). At low power magnification, a 
biphasic population resembling the morphology of t(6;11) renal cell carcinoma 
were easily observed (C). At high magnification, prominent nucleoli is a common 
characteristic (D).  
 
 
Immunohistochemical features 
The immunohistochemical results are reported in Table 3. Almost all cases 
(89%) were positive for PAX8 with a percentage of positive cells ranging from 
5% to 100%. Staining for cathepsin K was observed in thirteen of twenty tumors 
(65%). Among those, five tumors were positive for HMB45 with a percentage of 
positive cells ranging from 5% to 100%; whereas all cathepsin K negative tumors 
were also negative for HMB45 . The three multicystic tumors were the only cases 
immunolabeled for Melan-A. Eleven of eighteen tumors (61%) were positive for 
MET with a percentage of positive cells that ranged from 1% to 100%.  All the 
tumors examined were negative for CD68 (PG-M1) and AXL. 
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Table 3.  Immunohistochemical features of Xp11 renal cell carcinoma 
Case PAX 8 Cathepsin K HMB45 MelanA CD68(PG-M1) MET AXL 
1 5%+ 80%+ 15%+ neg neg 10% ++ neg 
2 80%+ 100% + neg 70%+ neg 10% + neg 
3 90%+ 100% + neg 80%+ neg 70% ++ neg 
4 5%+ 100% + neg neg neg 30%++ / 20%+ neg 
5 n.a. 90% + neg n.a. n.a. neg neg 
6 neg 100% + 100% + neg n.a. 1% + neg 
7 neg 90% + neg neg neg neg neg 
8 5%+ 100% + 5%+ neg neg 5% + neg 
9 100%+ 100% + neg neg neg 100% ++ neg 
10 100%+ 100% + neg 10%+ neg neg neg 
11 70% + 90% + 89% + neg neg 10% ++ neg 
12 60%+ 30% + 5% + neg neg neg neg 
13 90% + 80% + neg neg n.a. n.a. neg 
14 10%+ neg neg neg neg 5% + neg 
15 50%+ neg neg neg neg neg neg 
16 90 % + neg n.a. n.a. neg n.a. neg 
17 n.a. neg neg n.a. n.a. n.a. neg 
18 100% + neg neg neg n.a. neg neg 
19 100% + neg neg neg neg 50% ++ / 30%+ neg 
20 n.a. n.a. n.a. n.a. n.a. n.a. neg 
21 n.a. n.a. n.a. n.a. n.a. neg neg 
22 90% + neg n.a. n.a. n.a. 100% +++ neg 
n.a.: not available 
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Figure 3. Xp11 renal cell carcinoma showing PAX8 (A), cathepsin K (B), 
MART1 (C), HMB45 (D) positivity and CD68 (PG-M1) negativity (E). Xp11 
carcinoma harbouring both TFE3 translocation and increased gene copy number 
evaluated by FISH (F). 
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Figure 4. Immunohistochemical expression of MET in Xp11 renal cell carcinoma 
strong (A), intermediate (B) and mild staining (C). All Xp11 renal cell carcinomas 
were negative for AXL (D). 
 
 
 
FISH results  
The results of FISH analysis are detailed in Table 4. All twenty-two Xp11 
renal cell carcinomas demonstrated a high frequency of split TFE3 fluorescent 
signals ranging from 45% to 94% (mean 68%, median 75%). All cases but one 
were disomic for gene TFE3, TFEB and VEGFA. Case 4 showed an increased 
number of gene copy of TFE3, TFEB and VEGFA (4-5 signals).  
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Table 4. FISH results of Xp11 renal cell carcinomas  
Case TFE3 (percentage) TFE3 status  VEGFA  VEGFA status  TFEB  TFEB status 
1 Break (45 %) Rearranged 
Disomic 
70% 2 signals 
30% 4  signals 
Disomic No break Not rearranged    
Disomic 
2 Break (75 %) Rearranged 
Disomic 
100% 2  signals Disomic No break Not rearranged    
Disomic 
3 Break (50 %) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged    
Disomic 
4 Break (85 %)         
  4-5 signals 
Rearranged + GCN 
gains 
90% 4/5 signals   GCN gains No break      4-5 
signals 
Not rearranged 
GCN gains 
5 Break (60%) Rearranged 
Disomic 
90% 2 signals 
10% 3 signals 
Disomic No break Not rearranged  
Disomic 
6 Break (55 %) Rearranged 
Disomic 
100% 2  signals Disomic No break Not rearranged  
Disomic 
7 Break (60 %) Rearranged 
Disomic 
100% 2  signals Disomic No break Not rearranged  
Disomic 
8 Break (80 %) Rearranged 
Disomic 
100% 2  signals Disomic No break Not rearranged  
Disomic 
9 Break (50 %) Rearranged 
Disomic 
100% 2  signals Disomic No break Not rearranged  
Disomic 
10 Break (55 %) Rearranged 
Disomic 
85% 2  signals  
15% 3  signals 
Disomic No break Not rearranged  
Disomic 
11 Break (65 %) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
12 Break (75 %) Rearranged 
Disomic 
100% 2  signals Disomic No break Not rearranged  
Disomic 
13 Break (90 %) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
14 Break (75 %) Rearranged 
Disomic 
90% 2  signals  
10% 3  signals 
Disomic No break Not rearranged  
Disomic 
15 Break (90 %) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
16 Break (65%) Rearranged 
Disomic 
100% 2  signals Disomic No break Not rearranged  
Disomic 
17 Break (55%) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
18 Break (75 %) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
19 Break (50 %) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
20 Break (70 %) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
21 Break (80 %) Rearranged 
Disomic 
90% 2  signals 
10% 3  signals 
Disomic No break Not rearranged  
Disomic 
22 Break (75%) Rearranged 
Disomic 
n.a. n.a. No break Not rearranged  
Disomic 
n.a.: not available; GCN: gene copy number 
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t(6;11) renal cell carcinoma and TFEB-amplified renal cell carcinoma 
 
Clinical features 
 The clinical characteristics of the 10 patients are detailed in Table 5. Five 
patients were female and five male (F:M ratio, 1:1). The patients’ ages at 
diagnosis ranged from 19 to 80 years (mean 45, median 41). One patient (case 27) 
had history of non Hodgkin lymphoma treated with chemotherapy and a biopsy 
was performed when the renal mass was discovered. In case 23, a diagnosis 
suggesting oncocytoma was made in a core biopsy sample from different 
institution. Follow up was available for all patients, ranging from 2 to 78 months 
(mean 39, median 41). Two of them developed metastasis: patient 28 showed 
paratracheal and pleural metastasis 24 months after the surgery and died of 
disease after 46 months; patient 29 recurred with nodules in the perinephric fat 
and pelvic soft tissue after 24 months and he was alive 48 months after the radical 
nephrectomy. Patient 30, HCV infected, initially presented to the emergency 
department complaining abdominal pain. He underwent a CT scan, a renal mass 
was discovered and he underwent radical nephrectomy. Patient 31 and 32 suffered 
from abdominal pain due to lithiasis of upper urinary tract. In both cases, the renal 
mass was an incidental finding (Figure 5) and both patients were treated by partial 
nephrectomy. Follow up was available for all patients, ranging from 14 to 48  
months (mean 34, median 33). Patient 30 recurred with multiple nodules adjacent 
to the pancreatic tail, in the perinephric fat infiltrating the psoas muscle, and in the 
paravertebral region after 5 months. Sutent (sutinitib) was initiated; however, due 
to hematological and gastrointestinal toxicities, the treatment was stopped after 
two weeks. He is currently receiving cabozantinib, and he is alive 14 months after 
the radical nephrectomy. 
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Table 5. Clinical and pathological features of renal cell carcinomas with TFEB gene alterations 
       
Case Age Gender Size/Laterality Stage TNM Surgery Follow up 
23 19 F 5.5cm/L pT1bNxMx Partial nephrectomy 15 months alive 
24 54 F 7cm/R pT1bNxMx Radical nephrectomy 36 months alive 
25 20 F 9,5cm/R pT2aNxMx Radical nephrectomy 36 months alive 
26 55 M 3cm/R pT1aNxMx Partial nephrectomy 78 months alive 
27 34 M 7cm/L pT1bNxMx Partial nephrectomy 30 months alive 
28 42 F 10cm/L pT3aN0M1 Radical nephrectomy 
metastasis after 24 months, 
dead after 46 months 
29 33 M 8cm/L pT3aNxM1 Radical nephrectomy 
perinephric nodules after 24 
months, 48 months alive 
30 69 M 7cm/L pT2aNxMx Radical nephrectomy 
perinephric nodules after 5 
months, 14 months alive 
31 41 F 3cm/L pT1aNxMx Partial nephrectomy 20 months alive 
32 79 M 10cm/L pT2aNxMx Partial nephrectomy 18 months alive 
              
F: female, M: male, R: right, L: left 
    
Pathological features 
 The tumors ranged in size from 3 to 10 cm (mean and median 7) (Figure 
5). All but one was solid and tan mass (Figure 5), the smallest tumor was solid 
and cystic (Figure 5). Grossly, in the cases treated by radical nephrectomy, renal 
vein invasion was not identified. The histological features are described separately 
for completeness.  
Case 23 
 A discontinuous thick pseudocapsule with dystrophic calcification was 
present. The tumor was composed of epithelioid cells with eosinophilic and 
focally clear cytoplasm and small nucleoli (G2 by ISUP/WHO 2016) mainly 
arranged in solid-alveolar architecture (Figure 6). Areas with tubular and 
microcystic pattern were seen. Neither necrosis nor mitotic activity was found (<1 
per 10HPF). 
Case 24 
 A discontinuous pseudocapsule was present. The neoplasm was mainly 
composed of nests and tubules of polygonal cells with well-defined cell borders, 
clear cytoplasm and central round nuclei with prominent nucleoli (G3 by 
ISUP/WHO 2016). Additional areas showing cells with granular and eosinophilic 
cytoplasm were present. Tubular and micropapillary structures were also 
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observed. Smaller cells with dark nuclei clustering around hyaline material were 
focally seen. Mitotic figures were occasionally encountered (0-1 per 10 HPF). No 
necrosis was found. 
 
 
Figure 5. The most common macroscopic appearance of t(6;11) renal cell 
carcinoma: a solid (A) and tan mass (B). Only one tumor displayed a solid and 
cystic architecture (C-D). 
 
 
Case 25 
 The tumor was partially circumscribed by a fibrous pseudocapsule and 
made up of granular eosinophilic polygonal cells with conspicuous nucleoli (G2 
by ISUP/WHO 2016) arranged in solid and solid/alveolar architecture. At low 
power magnification, smaller lymphocyte-like cells grouped around collagenous 
spherules formed by basement membrane material were easily observed. 
Additional areas with microcysts were focally present. A few psammoma bodies 
and 1 mitotic figure per 10 HPF were found. No necrosis was observed. 
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Case 26 
 The tumor was solid and cystic and well-delineated by a pseudocapsule. 
The cells lining the cysts showed abundant vacuolated clear and eosinophilic 
cytoplasm with round nuclei and pinpoint nucleoli (G2 by ISUP/WHO 2016). 
Brownish pigment and psammoma bodies were extensively present. Mitotic 
figures were occasionally seen (0-1 per 10 HPF). Necrosis was absent. 
Case 27 
 The biopsy showed an epithelial neoplasm made up of sheets of small cells 
with round hyperchromatic nuclei and eosinophilic cytoplasm. In the resected 
specimen, the tumor consisted of a mixture of epithelioid cells with clear and 
granular eosinophilic cytoplasm and indistinct nucleoli (G2 by ISUP/WHO 2016) 
(Figure 6). Architecturally, solid areas, microcystic and papillary changes (Figure 
6) and bony metaplasia were observed. Areas of hyalinized stroma with 
calcification and hyalinized vessels were present (Figure 6). Mitotic figures were 
occasionally seen (1 per 10 HPF). No necrosis was observed.  
Case 28 
 Primary tumor: The tumor showed pushing margins and it was partially 
delineated from renal parenchyma by a pseudocapsule. However, an infiltrative 
growth pattern in the perinephric fat was focally present. The neoplastic cells were 
large and epithelioid with abundant clear cytoplasm and enlarged hyperchromatic 
nucleoli (G3 by ISUP/WHO 2016) (Figure 7). Hyaline sclerosis with eosinophilic 
material around vessels, dystrophic calcification and bony metaplasia were 
present throughout the tumor. Minimal mitotic activity was encountered (<1 per 
10HPF) in most of the neoplasm. Focal necrosis was seen (Figure 7). An 
additional area of neoplastic overgrowth was found. This area measured roughly 
1.5 cm and was characterized by small eosinophilic cells (G3 by ISUP/WHO 
2016) with necrosis and higher mitotic activity (15 per 10 HPF). Eight hilar lymph 
nodes were examined and were negative for tumor metastasis. 
Metastatic tumor: Biopsy material of pleural metastasis was available for 
histological characterization and consisted of clear cells with distinct borders and 
small round nuclei (Figure 7). No necrosis or mitotic activity was observed. 
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Case 29 
Primary tumor: The tumor was characterized by cells with clear to 
eosinophilic cytoplasm and small nuclei (G2 by ISUP/WHO 2016) arranged in 
solid-alveolar pattern and focal papillary architecture. A few mitotic figures were 
encountered (3 per 10 HPF). Necrosis was absent. 
Metastatic tumor: The same features were observed in metastatic nodules 
in perinephric fat and pelvis (Figure 7). Higher mitotic activity was found (5 per 
10 HPF). 
Case 30 
A discontinuous thick fibrous pseudocapsule was present. The tumor was 
predominantly composed of epithelioid cells with eosinophilic and focally clear 
cytoplasm and prominent nucleoli (G3 by ISUP/WHO 2016) mainly arranged in 
solid-alveolar architecture (Figure 8). In some areas smaller epithelioid clear cells 
were observed. Hemosiderin-laden histiocytes and extensive tumoral necrosis 
were noted. 
Case 31 
The tumor was well-delineated by a fibrous pseudocapsule and 
characterized by a tubulocystic pattern with a thin eosinophilic fluid material 
filling the cystic spaces. The single layer of cuboidal cells lining the tubules and 
the cysts showed abundant granular eosinophilic cytoplasm with round nuclei and 
pinpoint nucleoli (G2 by ISUP/WHO 2016) (Figure 8). Few macrophages bearing 
hemosiderin pigment were observed. Neither necrosis nor mitotic activity was 
found (<1 per 10HPF). 
Case 32 
A thick fibrous pseudocapsule was present. The solid area of the neoplasm 
was mainly composed of medium-sized polygonal cells with eosinophilic and 
more rarely clear cytoplasm arranged in a alveolar and less frequently tubular-
acinar or pseudopapillary (Figure 8). The nuclei showed prominent nucleoli (G3 
by ISUP/WHO 2016). Mitotic figures were occasionally encountered (0-1 per 10 
HPF). Tumoral necrosis and hemorrhage were found. 
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Figure 6. Different histologic appearances of t(6;11) renal cell carcinoma. Large 
epithelioid eosinophilic (A, B) and clear cells. Areas with microcystic (D) and 
papillary (E) pattern. Hyaline sclerosis with eosinophilic material around vessels, 
a pattern reminiscent of epithelioid angiomyolipoma (F).  
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Figure 7. t(6;11) renal cell carcinomas with aggressive behavior. The broad and 
epithelioid clear cells of case 6 (A) with focal necrosis (B). A biopsy of pleura 
showing clear cell with distinct borders and small round nuclei (C). Nodules in 
perinephric fat displayed a solid-alveolar pattern, note the clear to eosinophilic 
epithelioid cells (insert) (D). Expression of Melan-A (E) and cathepsin K (F) in 
tumor metastasis. 
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Figure 8. Histologic features of TFEB-amplified renal cell carcinomas. Low 
power view of case 8 shows a neoplasm with tumoral necrosis composed of 
epithelioid cells with eosinophilic (A) and clear cytoplasm and prominent nucleoli 
(B). The tumor of case 9 was composed of variably-sized cysts (C) lined by a 
single layer of cuboidal cells with eosinophilic cytoplasm and small round nuclei 
(D). Two different architectures of case 10 were present, tubular-acinar (E) and 
solid areas made up of medium-sized polygonal cells with eosinophilic cytoplasm 
and prominent nucleoli (F). 
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Immunohistochemical features 
 The immunohistochemical results are tabulated in Table 6. All t(6;11) 
renal cell carcinomas were positive for cathepsin K, and CD68 (KP1 clone) 
whereas expression for Melan-A and CK8-18 was observed in all tumors with 
different percentages (Figure 7). Staining for PAX8 and HMB45 was found in 7 
of 8 tumors and in 6 of 8 tumors respectively. In the overgrowth area of case 23, 
the immunohistochemical expression of the markers was the same. Both TFEB-
amplified renal cell carcinomas immunostained for PAX8, CK8-18 and cathepsin 
K, whereas just one tumor was positive for HMB45 and Melan-A. CD68 (PG-M1) 
was negative in all tumors (Figure 10). Staining for MET was observed in 5 of 7 
t(6;11) renal cell carcinomas tested whereas none of the 7 tumors expressed AXL. 
 All seven pure epithelioid PEComa /epithelioid angiomyolipomas labeled 
for cathepsin K, melanocytic markers (HMB45 and Melan-A) and CD68 (both 
PG-M1 and KP1 clones) and were negative for PAX8 (Figure 9).  
 
Table 6. Immunohistochemical results of renal cell carcinomas with TFEB gene alterations   
Case  PAX8 CK8-18 Cathepsin k HMB45 Melan A 
CD68(PG-
M1) 
MET AXL 
23 80% + 15% 100% + 5% + 80%+ neg 
50% ++/ 20% + neg 
24 80% + 30% 70% + 5% + 80% + neg 
neg neg 
25 10% + 70% 70% + 5% + 20% + neg 
5% + neg 
26 70% + 30% 100% + 5% + 80% + neg 
40% ++/ 20% + neg 
27 60% + 10% 90% + 5% + 80% + neg 
70% ++/ 20% + neg 
28 20% + 5% 80% + 10% + 80% + neg 
5% + neg 
29 neg 10% 100% + neg 5% + neg 
20% + neg 
30 30%+ 40% 40%+ neg 90%+ neg 
n.a. n.a. 
31 50%+ 50% 100% + 1%+ 5%+ neg 
n.a. n.a. 
32 50%+ 20% 10%+ neg neg neg 
n.a. n.a. 
n.a.: not available 
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Figure 9. t(6;11) renal cell carcinoma (A) showing cathepsin K (C) and PAX8 (E) 
positivity and CD68 PG-M1 negativity (G). Pure epithelioid PEComa/epithelioid 
angiomyolipoma (B) expressing cathepsin K (D). On the contrary of t(6;11) renal 
cell carcinoma, pure epithelioid PEComa/epithelioid angiomyolipoma was 
negative for PAX8 (F) but positive for CD68 PG-M1(H). 
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FISH results 
 All eight t(6;11) renal cell carcinomas and two metastasis demonstrated a 
high frequency of split TFEB fluorescent signals (Figure 11) ranging from 61% to 
94% (mean 74%, median 75%) detailed in Table 7. In all these samples the 
distance of red and green signals was greater than twice signal diameter. In two 
tumors (case 28 and 29) increased gene copy number was observed (3-5 
fluorescent signals per neoplastic nuclei) (Figure 11). In case 28, the increased 
number of fluorescent signals was mainly observed in the overgrowth nodule. 
Both tumors showed increased number of CEP6 (3-4 copies) whereas the 
remaining four tumors were disomic. The remaining three cases showed a high 
level of TFEB gene amplification (>10 copies of fluorescent signals), one with 
TFEB rearrangement, the other two without evidence of rearrangement (Figure 
10). VEGFA was amplified in all three cases with TFEB amplification. In two of 
them (case 30 and case 32), the levels of amplification of VEGFA and TFEB were 
identical, whereas in case 31 the level of amplification of VEGFA was lower than 
the level of TFEB (Table 7). 
None of the 37 control tumors showed split TFEB fluorescent signals. Minimally 
split fluorescent signals in which fluorescent signals were separated by a signal 
diameter were occasionally observed (mean 3.8%, median 3%, range from 0% to 
10%); these were considered artifactual and no significant.  
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Table 7. Molecular results of renal cell carcinomas with TFEB gene alterations 
Case TFEB FISH 
TFE3 
FISH CEP6 
VEGFA 
FISH 
VEGFA 
RNAscope 
TFEB status 
by FISH 
VEGFA 
status by 
FISH 
VEGFA status by 
RNAscope 
23 Break (74%) no break 2-3 signals 2-3 signals 4 rearranged disomic positive 
24 Break (80%) no break 2 signals 2 signals 1 rearranged disomic negative 
25 Break (75%) no break 2 signals 2-3 signals 1-2 rearranged disomic negative 
26 Break (65%) no break 2 signals 2 signals 3-4 rearranged disomic positive 
27 Break (78%) no break 2-3 signals 2-3 signals 4 rearranged disomic positive 
28 
Break (94%)                           
3-5 signals 
no break                     
3 signals 3-4 signals 3 signals 4 
rearranged + 
GCN gains GCN gains positive 
29 
Break (61%)                           
3-5 signals no break 3-4 signals 4-5 signals 3-4 
rearranged + 
GCN gains GCN gains positive 
30 
Break (75%) 
>10 signals no break 2 signals > 10 signals 3 
rearranged + 
amplified 
 
amplified positive 
31 
No break 
>10 signals 
no break 3 signals 
> 10 signals 
(10% of 
nuclei)   
6 signals 
(90% of 
nuclei) 
4 amplified amplified positive 
32 
No break  
>10 signals 
no break 4 signals 
> 10 signals 
(80% of 
nuclei)  
6 signals 
(20% of 
nuclei) 
3-4 amplified amplified positive 
GCN: gene copy number 
  
41 
 
 
Figure 10. Immunophenotype of TFEB-amplified renal cell carcinomas. PAX 8 
was positive in the neoplastic cells of case 30 (A). The cells lined the cysts of case 
31 were strongly positive for cathepsin K (high magnification in the insert) (B). 
Staining for Melan-A was diffusely present in the tumor cells of case 32 (C). 
Fluorescence in situ hybridization result of case 30 shows TFEB amplification 
(D). The green and red signals are split apart demonstrate the break of the TFEB 
gene (insert). TFEB gene amplification of case 32 (E) with identical level of 
amplification of VEGFA (F) and high VEGFA mRNA expression (G). 
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RNAscope results 
Overall, VEGFA mRNA expression was observed in 8 of 10 (80%) renal 
cell carcinomas with TFEB gene alteration (Table 7). Of these 8 cases positive for 
VEGFA staining, three cases showed high level TFEB amplification, one case 
showed TFEB rearrangement with increased TFEB gene copy number, while four 
showed TFEB gene rearrangement without increased copy number (Figure 10). 
None of the papillary renal cell carcinomas, chromophobe renal cell carcinomas 
and oncocytomas demonstrated a positive staining for VEGFA whereas two of 
three clear cell renal cell carcinomas showed a high VEGFA mRNA expression.  
 
Cytogenetic results 
 Fresh tumor samples were available for karyotype analysis in 2 of 10 
tumors (case 24 and case 27). The karyotype result of case 24 was previously 
reported
28
. In case 27, all the analyzed cells showed the translocation 
t(6;11)(p21;q12) (Figure 11). A subset of these cells, about 20%, showed 
additional rearrangements including monosomy of chromosome 22 and 
translocation of almost its entire long arm on the short arm of chromosome 8, as 
showed by FISH results in which both the probes mapping in 22q11.2 and q13.3 
are located on the rearranged chromosome 8. 
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Figure 11. All t(6;11) renal cell carcinomas demonstrated TFEB rearrangement 
(A). Note the increased number of fluorescent signals in cases with aggressive 
behavior (B). Representative QFQ banded karyotype of the tumor (case 27): 46, 
XY, t(6;11)(p21;q12) karyotype (C). 
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Literature review and comparison of aggressive and non-aggressive t(6;11) 
renal cell carcinoma 
Aggressive t(6;11) renal cell carcinoma. The results of the literature 
review 
14, 20, 21, 26, 29-32
 and the new two aggressive cases of t(6;11) renal cell 
carcinoma are summarized in Table 8. The mean age of these patients was 46 
years and the median 42 years (range from 33 to 77). There was a male 
predominance (8M, 3F), with a male-to-female ratio of roughly 2.6:1. The 
tumors’ size ranged from 3 to 27 cm (mean 12, median 10). Follow up for these 
cases ranged from 3 to 120 months (mean 59, median 48). Among the eleven 
patients, four died for disease. All of them developed metastasis. In decreasing 
order of frequency, the metastatic sites were lung (3 cases), bone (3 cases), liver 
(2 cases), lymph nodes (2 cases), perinephric fat and pelvic soft tissue (1 case), 
vagina (1 case). In one patient, the site of metastasis was not specified.  
Non-aggressive t(6;11) renal cell carcinoma. The new cases of t(6;11) 
renal cell carcinoma and the results of the literature review
14, 19-23, 26, 28, 30, 31, 33-45
 
are presented in Table 9. Overall, 53 cases of t(6;11) renal cell carcinoma were 
found. The mean age of these patients was 30 years and the median 29 years 
(range from 3 to 68). There was no gender predominance (26M, 25F). The 
tumors’ size ranged from 1 to 19 cm (mean and median 7). When follow up was 
available, it ranged from 2 to 60 months (mean 27 and median 25). 
Comparison of aggressive and non-aggressive t(6;11) renal cell carcinoma. 
There is a statistically significant difference in age and tumors’ size between 
aggressive and non-aggressive tumors. The aggressive tumors occur in older 
patients (p=0.007) and tend to be larger (p=0.04). Although there is a prevalence 
of aggressive t(6;11) renal cell carcinoma in men, no significant difference in 
gender was found (p=0.32).  
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Table 8. Aggressive t(6;11) renal cell carcinomas  
 
Case  References Age Gender Size (cm) Stage TNM Karyotype/FISH Follow up Notes 
1 
Camparo et al., 
2008 36 M 20 pT3bN2M1 NA* 
dead after 3 
months multiple metastasis 
2 
Ishihara et al., 
2011 45 M 7 pT3aN1M1 NA 
7 months 
alive 
lung and vertebral 
metastasis 
3 
Argani et al., 
2012 42 M 27 pT3NxM1 break apart probe NA liver metastasis 
4 
Argani et al., 
2012 60 M 14 pT3bN0M1 break apart probe NA 
liver metastasis + IVC 
thrombus 
5 
Inamura et al., 
2012 37 M NA NA 
t(6;11)(p21.1;q12 
13) 
dead after 
120 months lung metastasis  
6 
Peckova et al., 
2014 77 F 12  pT3NxM1 
RT-PCR + break 
apart  
dead after 2,5 
months 
adrenal gland and 
lung metastasis 
7 
Smith et al., 
2014 34 M 3 pT1NxM1 break apart probe 
96 months 
alive rib metastasis  
8 
Lilleby et al., 
2015 42 M NA NA break apart probe 
97 months 
alive 
vertebral and rib 
metastasis  
9 
Argani et al., 
2016  61 F 19 pT4N0M1 break apart probe 
18 months 
alive vaginal metastasis 
10 
Present series 
(case 28) 42 F 10 pT3aN0M1 break apart probe 
dead after 46 
months lung metastasis 
11 
Present series 
(case 29) 33 M 8 pT3aNxM1 break apart probe 
48 months 
alive 
perinephric and pelvic 
soft tissue tissue 
nodules 
M: male, F: female, NA: not available, IVC: inferior vena cava 
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Table 9. Non aggressive t(6;11) renal cell carcinomas  
Case References Age Gender Size (cm) Stage TNM Karyotype/ FISH Follow up Notes 
1 
Argani et al., 2001 
Davis et al., 2003 
Argani et al., 2005 
18 M 7 pT1bNxMx t(6;11)(p21.1;q12) 18 months 
 
2 Argani et al., 2001 
Argani et al., 2005 
Martignoni et al., 2009 
10 M 12 pT2NxMx t(6;11)(p21.1;q12) 26 months 
 
3 Kuiper et al., 2003 
Dijkhuizen et al., 1996 
42 F NA NA t(6;11)(p21;q13) NA 
 
4 Kuiper et al., 2003 
Dijkhuizen et al., 1996 
17 F NA NA t(6;11)(p21;q13) NA 
 
5 Kuiper et al., 2003 
Argani et al., 2005 
Martignoni et al., 2009 
14 F 4.5 pT1bNxMx t(6;11)(p21;q13) NA 
 
6 Davis et al., 2003 
Argani et al., 2005 
18 F 2.8 pT1aNxMx 
t(6;11)(p21.1;q12)+ 
break apart 
18 months 
 
7 Argani et al., 2005 
Martignoni et al., 2009 
20 F 9.5 pT2NxMx RT-PCR 30 months 
 
8 Argani et al., 2005 
Geller et al., 2008 
Martignoni et al., 2009 
9 F 2 pT1aNxMx RT-PCR NA 
post 
chemotherapy 
(nephroblastoma) 
9 Argani et al., 2005 
Martignoni et al., 2009 
33 M 6 pT1bNxMx RT-PCR NA 
 
10 Argani et al., 2006 
Martignoni et al., 2009 
6 F 5 pT1bNxMx t(6;11)(p21;q12) 3 months 
post 
chemotherapy 
(nephroblastoma) 
11 
Pecciarini et al., 2007 
Martignoni et al., 2009 
Petterson et al., 2014 
Present series (case 2) 
54 F 7 pT1bNxMx t(6;11)(p21;q12) 36 months 
 12 Camparo et al., 2008 34 F 15 pT2N0M0 t(6;11)(p21;q13) 50 months 
 
13 Hora et al., 2009 
Petterson et al., 2012 
Peckova et al., 2014 
22 M 4 pT1bNxMx NA 40 months 
 
14 Hora et al., 2009 
Petterson et al., 2012 
Peckova et al., 2014 
24 F 13.6 pT2NxMx NA* 18 months pregnant 
15 Hora et al., 2009 39 F 1 pT1aNxMx NA 13 months 
 16 Zhan et al.,  2010 26 M 4.3 pT1bNxMx RT-PCR 6 months 
 17 Malouf et al., 2011 NA NA NA NA NA* NA 
 
18 
Suarez Villa et al., 
2011 22 M 10 pT2NxM0 NA* NA 
 19 Argani et al., 2012 14 F NA NA break apart probe NA 
 20 Argani et al., 2012 37 M 4 pT1aNxMx break apart probe NA 
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21 Argani et al., 2012 3 F 2 pT1aNxMx break apart probe NA 
 22 Argani et al., 2012 58 F 3 pT1aNxMx break apart probe NA 
 23 Argani et al., 2012 34 M 1.8  pT1aNxMx break apart probe NA end stage kidney 
24 Argani et al., 2012 25 M 15 pT2NxMx break apart probe NA 
 25 Inamura et al., 2012 57 M 10.2  pT2NxMx NA* 8 months 
 
26 
Inamura et al., 2012 47 M 3.2  pT1aNxMx 
t(6;11)(p21.1;q12 
13) 12 months 
 
27 
Petterson et al., 2012 
Peckova et al., 2014 
Present series (case 3) 20 F 9.5  pT2NxMx t(6;11) (p21;q12) 60 months 
 
28 Petterson et al., 2012 
Peckova et al., 2014 54 F 7 pT1bNxMx t(6;11) (p21;q12) 36 months 
 29 Rao et al., 2012 31 F 9 pT2NxMx break apart probe 6 months 
 30 Rao et al., 2012 21 M 4 pT1aNxMx break apart probe 22 months 
 31 Rao et al., 2012 37 F 3 pT1aNxMx break apart probe 34 months 
 32 Rao et al., 2012 36 F 2.5 pT1aNxMx break apart probe NA 
 33 Rao et al., 2012 30 M 9 pT2NxMx break apart probe 31 months 
 34 Rao et al., 2012 29 F 4.5 pT1bNxMx break apart probe 55 months 
 35 Rao et al., 2012 30 M 4 pT1aNxMx break apart probe 36 months 
 36 Zhong et al., 2012 17 M 19 pT2NxMx NA* NA 
 37 Rao et al., 2013 68 M 2,5 pT1aNxMx break apart probe 23 months 
 38 Peckova et al., 2014 15 M 10 pT2NxMx break apart probe 12 months 
 
39 
Matsuura et al., 2014 40 M NA NA 
MALAT1(alpha)–
TFEB NA 
 40 Smith et al., 2014 NA NA NA NA break apart probe NA 
 41 Smith et al., 2014 44 M 7.8  pT2NxMx break apart probe NA 
 42 Smith et al., 2014 9 M 4 pT1aNxMx break apart probe NA 
 43 Smith et al., 2014 3 F NA NA break apart probe NA 
 44 Smith et al., 2014 23 M 10 pT2NxMx break apart probe NA 
 45 Smith et al., 2014 9 F 9 pT2NxMx break apart probe NA 
 46 Smith et al., 2014 46 M 15 pT2NxMx break apart probe NA 
 47 Smith et al., 2014 68 M 2.8 pT1aNxMx break apart probe NA 
 48 Smith et al., 2014 62 M 3 pT1aNxMx break apart probe NA 
 49 Arneja et al., 2015 11 M 13.7 pT2NxMx break apart probe NA 
 50 Argani et al., 2016  61 M 2.7 pT1aNxMx break apart probe NA 
 51 Present series (case 26) 55 M 3 pT1aNxMx break apart probe 78 months 
 52 Present series (case 27) 34 M 7 pT1bNxMx break apart probe 30 months 
 53 Present series (case 23) 19 F 5.5 pT1bNxMx break apart probe 2 months 
 
M: male, F: female, NA: not available 
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DISCUSSION  
In this study, we collected a large series of MiT family translocation renal 
cell carcinoma and we analyzed 1) immunohistochemical diagnostic markers 
since the differential diagnosis is challenging, especially with pure epithelioid 
PEComa/epithelioid angiomyolipoma; 2) a proper cut-off  by fluorescence in situ 
hybridization to reach the correct diagnosis; 3) possible predictive markers in 
tumor tissue for target therapy.  
We have evaluated the possible usefulness of CD68 as 
immunohistochemical marker to differentiate MiT family translocation renal cell 
carcinoma from pure epithelioid PEComa /epithelioid angiomyolipoma. 
Distinguishing those two entities is clinically important since mTOR inhibitors are 
a therapeutic option for the latter 
46
, and, in our experience, the differential 
diagnosis of MiT family translocation renal cell carcinoma, especially t(6;11) 
renal cell carcinoma with pure epithelioid PEComa /epithelioid angiomyolipoma 
is the most difficult. Both tumors are composed of medium and large cells with 
clear or faintly granular eosinophilic cytoplasm and enlarged nuclei usually with 
prominent nucleoli. As described in this study and previously reported 
42, 47
, 
t(6;11) renal cell carcinoma may show hyalinized areas with thick-walled vessels 
mimicking the abnormal blood vessels in the angiomyolipoma. Moreover, the two 
entities share the immunohistochemical expression of melanocytic markers and 
cathepsin K and both are often negative for cytokeratin 
48
. Staining for PAX8 has 
been demonstrated a useful tool in this challenging diagnosis. In this study we 
found that all but three FISH-confirmed MiT family translocation renal cell 
carcinomas were positive for PAX8 and 7 pure epithelioid PEComa/epithelioid 
angiomyolipomas were consistently negative. As we previously reported 
24
, either 
CD68 (PG-M1) or CD68 (KP1) labeled pure epithelioid PEComa /epithelioid 
angiomyolipomas. On the other hand, all MiT family translocation renal cell 
carcinomas were completely negative for CD68 (PG-M1) but positive for CD68 
(KP1), supporting the usefulness of CD68 (PG-M1) along with PAX8 in 
distinguishing MiT family translocation renal cell carcinoma from pure 
epithelioid PEComa /epithelioid angiomyolipoma. The absence of CD68 (PG-M1) 
was surprising in that TFEB/TFE3 are known to be master regulators of lysosomal 
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proteins expression, and it thought to drive expression of cathepsin K in the MiT 
family translocation renal cell carcinoma. A possible explanation could be 
attributed to the different epitopes recognized by the two different clones; the 
epitope recognized by CD68 (PG-M1) might be lost or masked during 
carcinogenesis.  
Another important aspect of this study is the proper cut-off to define the 
occurrence of TFEB rearrangement in t(6;11) renal cell carcinoma and TFE3 
rearrangement in Xp11 renal cell carcinoma. Using standard criteria determined 
by scoring normal tissues for clinical assays, Argani et al. 
20
 defined a positive 
FISH result in their clinical assay  as when the fluorescent signals were separated 
by a signal diameter >1 in at least 15.8% neoplastic cells using standardized 
published methodology. In this study, we observed a high frequency (74% and 
68%) of split signals ( ≥ 2 signals diameter) in t(6;11) renal cell carcinomas and 
Xp11 renal cell carcinomas, ranging from 61% to 94% and from 45% to 94%. 
Similar results have been published by Smith et al., reporting high frequency of 
split signals (range from 38% to 86%, mean 69%) in 10 cases of t(6;11) renal cell 
carcinoma 
21
.  
With regards to t(6;11) renal cell carcinoma, it is known that most 
instances have an indolent clinical course with a few published cases 
demonstrating aggressive behavior 
14, 20, 21, 26, 29-32
. In this study, we reported 2 
patients with t(6;11) renal cell carcinoma who both developed metastasis after 24 
months. In both cases, we histologically confirmed the metastasis and FISH assay 
was performed in primary and metastatic samples. In our review of the literature, 
we have identified nine t(6;11) renal cell carcinomas with aggressive behavior. 
Among them, in 2 tumors no molecular analysis for the presence of translocation 
(6;11) was carried out 
14, 29
, in the remaining karyotyping or FISH assay have 
revealed TFEB rearrangement.  owever, the recurrences have been usually 
reported as only a clinical finding.  n only one case, lung metastasis was 
histologically examined and the presence of t(6;11)(p21.1; 12  13) chromosomal 
rearrangement was demonstrated; that patient had a renal tumor diagnosed as 
“clear cell renal cell carcinoma” 8 years before which was not reevaluated for the 
presence of translocation 
30
. Interestingly, we also reported an increasing number 
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of TFEB fluorescent signals (3-5 signals) in the two aggressive cases of our series. 
This drew our attention since TFEB amplified renal cell carcinoma has been 
recently described 
26, 27, 49
.  Hence, we investigated the possibility of TFEB 
amplification and FISH analysis with a chromosome 6 centromeric probe. After 
the correction by chromosome 6 centromeric probe, we observed a similar 
increased number of TFEB and CEP6 fluorescent signals; therefore, we did not 
consider them as amplified tumors. Nevertheless, the occurrence of TFEB gene 
copy number gains is particularly interesting since both TFEB amplification and 
rearrangement have been demonstrated in two previously published primary 
tumors
26, 31
. It is worth noting that Peckova et al. reported the presence of 
amplification without any additional details whereas Argani et al. defined 
amplification as >10:1 ratio of TFEB fluorescent signal to centromeric probe. This 
aspect is fascinating because it is possible that increasing in copy number of 
TFEB gene region in t(6;11) renal cell carcinoma may predict an aggressive 
clinical course. In this light, we may speculate that the occurrence of TFEB gene 
copy number gains in our two aggressive cases might be the result of genomic 
instability. However, further investigations of larger series should be conducted to 
validate this result. 
  Overall, t(6;11) renal cell carcinomas described in this article occurred in 
patients around 40 years, the tumors’ size was 7.5 cm without a typical gross 
appearance (6 of 7 tumors were solid and one tumor extensively cystic). 
Interestingly, one patient (case 5) was previously treated with chemotherapy for 
the diagnosis of non Hodgkin lymphoma. However, the occurrence of t(6;11) 
renal cell carcinoma associated to a history of prior exposure to chemotherapy is 
known
9
. The characteristic biphasic morphology due to the presence of larger 
epithelioid cells and smaller cells surrounding basement membrane material was 
noted in 1 of 7 tumors (case 3). A discontinuous pseudocapsule was present in 5 
of 7 tumors and psammoma bodies were encountered in half tumors. Bony 
metaplasia and hyalinized stroma with thick-walled vessels were observed in two 
tumors. The cells typically showed nucleolar grade G2 and G3 by ISUP/WHO 
2016. Tumor necrosis was absent and the proliferation rate was low with the 
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exception of the two aggressive tumors in which focal necrosis and mitotic 
activity were found.  
With respect to aggressive t(6;11) renal cell carcinoma, the present series 
as well as the review of the literature provides some useful information. Renal cell 
carcinoma with TFEB rearrangement displayed an aggressive behavior in roughly 
17% of cases (11 of 64), occurring as larger masses (12 versus 7 cm) in older 
patients (46 versus 30 years). It should be noted that hematogenous metastasis are 
more common than nodal metastasis, which was reported in two cases without 
molecular confirmation of t(6;11) rearrangement. 
 An increasing number of manuscripts reported the presence of TFEB gene 
amplification in renal cell carcinoma 
26, 27, 50-52
. Since this tumor is defined by the 
occurrence of TFEB gene amplification what is considered amplified is of 
paramount importance. Gene amplification is established as an elevated extra 
copies of a gene without a proportional increase in other genes. Generally 
speaking, amplification of a gene may have diagnostic value (e.g. MDM2 
amplification in well-differentiated liposarcoma) 
53
, prognostic value (e.g. MYC 
amplification in neuroblastoma) 
54
 or predictive value (e.g. HER-2 amplification 
in breast carcinoma)
55
. In renal cell carcinoma, TFEB gene amplification seems to 
be correlated with an aggressive behavior. The threshold proposed by Argani and 
coauthors is defined by the presence of an average of 10 or more copies per 
neoplastic nucleus 
26
. Given the lack of a consensus to define TFEB amplification, 
Gupta et al. arbitrarily defined two levels of amplification, a low-level 
characterized by 5-10 copies and an high-level with >10 copies 
27
. Since the other 
studies used a cut-off of >10 copies per nuclei, we decided to consider the latter as 
the threshold to use. Moreover, in previous analysis 
26, 27, 50, 52
, no percentage of 
tumor cells harboring the amplification has been recorded, except in one recent 
study in which at least 10% of cells demonstrated the increasing fluorescent 
signals to consider the case amplified 
51
. In the present series, the 3 tumors with 
TFEB amplification showed an increased gene copy number in virtually all 
neoplastic nuclei.   
Another open and controversial issue is whether the increase of TFEB 
gene copy number is due to nonspecific whole DNA polyploidy versus locus 
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specific TFEB amplification, in other words, whether it is a specific or nonspecific 
event. After corrections for centromeric alpha-satellite specific for chromosome 6, 
TFEB gene copy number was interpreted as true amplification rather than an 
nonspecific polyploidy in three cases (case 30, case 31 and case 32). On the other 
hand, two cases (case 28 and case 29) showed a lower level of gene copy number 
(3-5 signals per tumor nuclei) with a similar increased number of CEP6. Hence, 
these were considered as chromosome 6 polysomy, a nonspecific event reflecting 
genomic instability.  
Because of its novelty, the characteristics of TFEB-amplified renal cell 
carcinoma are not well understood; therefore, we undertook a comprehensive 
review of this tumor as illustrated in Table 10. Overall, 42 cases of TFEB-
amplified renal cell carcinoma, including the 3 cases described herein, with or 
without TFEB rearrangement were found. The mean age of these patients was 63 
years and the median 65 years (range from 23 to 83). There was a slight male 
predominance (24M, 18F). The tumors’ size ranged from 1.8 to 19.5 cm (mean 
and median 10). When follow up was available, it ranged from 1 to 265 months 
(mean 79 and median 24). Based upon the review of the literature, the majority 
(26/41, 63%) of TFEB-amplified renal cell carcinomas are tumor stage pT3 or 
higher which correlates with the aggressiveness. Moreover, most of the tumors 
(88%) showed an high ISUP/WHO 2016 nucleolar grade. Interestingly, as  
previously noted 
27, 56
 and here reported, TFEB amplification may occur in low 
grade renal cell carcinoma. Histologically, the tumors with TFEB amplification 
were mainly characterized by a nested or papillary/psuedopapillary architecture 
made up of epithelioid cells with eosinophilic cytoplasm. None of the four t(6;11) 
renal cell carcinomas with concurrent TFEB gene amplification demonstrated the 
classical biphasic morphology with larger epithelioid cells and smaller cells 
clustered around eosinophilic spheres formed by basement membrane material. 
Nevertheless, the amplified - t(6;11) renal cell carcinoma (case 30) described in 
the present study showed two types of cells, large and small size. 
Immunohistochemically, labeling for HMB45, when reported present (6/27, 22%), 
is usually focal whereas the positivity of cathepsin K (14/21, 67%) and Melan-A 
(26/33, 79%) ranged from patchy to diffuse. Among the four cases of t(6;11) renal 
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cell carcinoma with concurrent TFEB gene amplification, all tumors expressed 
Melan-A, cathepsin K was present in 3 of 4, and half of them were labeled by 
HMB45. The expression of cathepsin K and melanocytic markers in TFEB-
amplified renal cell carcinoma is worthy of note. A possible explanation is that, 
not only TFEB rearrangement but also increased TFEB gene copy number leads to 
intact  TFEB protein overexpression which correlates with aberrant melanocytic 
marker immunolabeling and cathepsin K expression as well. 
In the current study, we have also assessed the occurrence of VEGFA 
amplification in renal cell carcinomas with TFEB gene alterations, either 
amplification or rearrangement. Increased VEGFA gene copy number (3-5 
signals) was found in the two aggressive cases of t(6;11) renal cell carcinoma with 
a similar number of TFEB fluorescent signals. In the three TFEB-amplified renal 
cell carcinomas (>10 TFEB signals), a concurrent VEGFA amplification was 
observed. The mRNA expression of VEGFA analyzed by RNAscope was 
concordant with VEGFA status in 7 out of 10 tumors (5 VEGFA mRNA positive 
cases with VEGFA and TFEB gene copy number/amplification and 2 VEGFA 
mRNA negative cases with VEGFA and TFEB disomic status). In the remaining 
three cases, the level of VEGFA mRNA was higher than expected based on the 
level of VEGFA gene copy number suggesting the involvement of an alternative 
mechanism leading the upregulation of mRNA expression.  
We have also analyzed 22 cases of Xp11 renal cell carcinoma. In the 
present series, Xp11 renal cell carcinoma occurred in patients around 40 years 
with almost equal prevalence in both sexes. Four patients (n. 4, 9, 13 16) were at 
advanced stage at the diagnosis with lymph node metastasis. One patient (n. 7) 
developed multiple peritoneal metastasis sixty months after the surgery. 
Regarding histology the tumors presented a wide spectrum of architectures and 
morphologies, as previously reported
3
. Interestingly three cases showed an almost 
identical growth pattern characterized by multiple cysts lined by medium sized 
cells with clear cytoplasm and G2 nuclear grade sec. WHO/ISUP 2016. 
These tumors shared an identical immunophenotype being diffusely positive for 
cathepsin K, Melan-A and negative for HMB45. It is of interest that those tumors  
were the only cases positive for Melan-A while all the others Xp11 renal cell 
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carcinomas were negative. Cases of extensively cystic Xp11 renal cell carcinoma 
have been recently described by Wang and colleagues
57
. In those tumors the TFE3 
gene was fused with the gene MED15, so it is possible to speculate that also the 
three cystic tumors herein reported are characterized by the same novel gene 
fusion. 
The last fascinating aspect regards the treatment. At present, there are few studies 
concerning the target therapy (mTOR inhibitor and anti-angiogenic including anti-
VEGF receptor and ligand) in MiT family translocation renal cell carcinoma 
15, 16
. 
It is important to note that all the tumors of the patients reported by Malouf et al. 
and Choueiri et al. were Xp11 renal cell carcinoma and data regarding the 
treatment of aggressive t(6;11) renal cell carcinoma are lacking. Recently, Gupta 
and colleagues described the possible usefulness of VEGFR target therapy in four 
renal cell carcinomas with TFEB/VEGFA coamplification 
27
. This finding is 
interesting since the t(6;11) renal cell carcinoma with aggressive behavior 
reported in the present study were characterized by increased TFEB/VEGFA gene 
copy number suggesting that VEGFA may be a potential therapeutic target in this 
subset of tumors. Moreover, a tyrosine kinase inhibitor with activity against 
VEGF, MET, and AXL has been recently proposed in the treatment of advanced 
renal cell carcinomas. It has been demonstrated in vitro the inhibition of the 
osteoclast differentiation, down-regulating several molecules such as cathepsin K, 
after non-cytotoxic doses of this treatment 
58, 59
. Some medical trials conducted on 
conventional renal cell carcinomas have shown that this drug could be highly 
effective in inducing tumor regression even in cases where antiangiogenetic drugs  
and m-TOR inhibitors have failed 
18, 60-62
.  
MET is a membrane receptor sensitive to hepatocyte growth factor and 
that activates an intracellular signalling pathway very important in the renal 
physiology. The hepatocyte growth factor in the kidney stimulates tissue 
regeneration following an insult, promotes the production of molecules with anti-
oxidant, anti-inflammatory functions and that inhibit fibrogenesis. In the cell it 
stimulates mitosis, migration and has antiapoptotic effects; therefore an 
unregulated activation of MET can promote oncogenesis and support tumor 
growth. It has been shown that TFE3 can be a strong promoter of MET 
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transcription and that the pathway of liver growth factor is important in the 
oncogenesis of tumors that have an over expression of TFE3 
18
. On the other 
hand, AXL is a tyrosine kinase receptor belonging to the subfamily of TAM 
receptors. It acts as a GAS6 receptor, a factor that stimulates cell growth. The 
signaling pathway activated by AXL promotes numerous cellular processes 
including proliferation, adhesion, migration and therefore AXL can act a pro-
oncogenic potential 
63
. 
Based upon the possibility to use a tyrosine kinase inhibitor with activity 
against VEGF, MET, and AXL we analyzed the immunohistochemical expression 
of MET and AXL in MiT family translocation renal cell carcinoma. The 
expression of these molecules in the tumor samples would provide an evidence to 
support the use of this drug in those cases.  In the present study, none cases 
showed AXL positivity, whereas 61% of Xp11 renal cell carcinomas and 70% of 
t(6;11) renal cell carcinomas were labeled for MET.  
 In summary, in this study we present the clinical, morphological and 
molecular features of a large series of MiT family translocation renal cell 
carcinoma and TFEB-amplified renal cell carcinoma. We report the high 
frequency of split signals by FISH in MiT family translocation renal cell 
carcinomas and the occurrence of gene copy number increases in the aggressive 
cases. We demonstrate the usefulness of CD68 (PG-M1) immunohistochemical 
staining in distinguishing MiT family translocation renal cell carcinoma from pure 
epithelioid PEComa /epithelioid angiomyolipoma. Finally, we suggest VEGF and 
MET as potential therapeutic target in aggressive MiT family translocation renal 
cell carcinomas  
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Table 10. Renal cell carcinomas with TFEB amplification  
  
Case  References Age Gender 
Size 
(cm) Stage TNM 
ISUP 
grade PAX2/PAX8 
Cathepsin 
K HMB45 
Melan-
A TFEB FISH 
VEGFA 
FISH 
Follow 
up Notes 
1 
Peckova et 
al, 2014 77 F 12  pT3NxM1 4  +  +  +  + 
break + 
amplification* NA 
dead 
after 
2,5 
months 
adrenal 
gland and 
lung 
metastasis 
2 
Durinck et 
al, 2014 56 M NA NA low NA NA NA NA NA NA NA 
 
3 
Argani et 
al, 2016 64 F 10.9 pT3bN2Mx 3  + neg neg  + >10 signals NA 
28 
months 
alive 
renal vein 
thrombus 
4 
Argani et 
al, 2016 71 M 3 pT3aNxMx 3  + neg neg  + >10 signals NA 
 
periaortic 
lymph 
node 
metastasis 
5 
Argani et 
al, 2016 65 M 1.9 pT1NxMx 3  +  + neg  + >10 signals NA NA 
 
6 
Argani et 
al, 2016 23 F 7 pT2NxMx 4  +  +  +  + >10 signals NA 
 
vaginal 
metastasis 
7 
Argani et 
al, 2016 77 F 4 pT1NxMx 3  +  +  +  + >10 signals NA NA 
 
8 
Argani et 
al, 2016 78 F 12 pT3bNxMx 3  +  + neg  + >10 signals NA NA 
renal vein 
thrombus 
9 
Argani et 
al, 2016 61 F 19 pT4N0M1 4  + neg neg  + 
break + >10 
signals NA NA 
vaginal 
metastasis 
10 
Argani et 
al, 2016 61 M 2.7 pT1NxMx 3  +  +  +  + 
break + >10 
signals NA NA 
 
11 
Williamson 
et al, 2016 57 M 19.5 pT3aN0Mx NA  +  + NA  + >10 signals NA NA 
 
12 
Williamson 
et al, 2016 62 F 12.5 pT3aNxMx NA NA neg neg neg >10 signals NA NA 
 
13 
Williamson 
et al, 2016 78 F 4.3 pT3aNxMx NA NA  + NA  + >10 signals NA NA 
 
14 
Williamson 
et al, 2016° 64 M 11 pT3aN0Mx NA NA NA NA NA >10 signals NA NA 
 
15 
Williamson 
et al, 2016° 59 M 9.2 pT2aN1Mx NA NA NA NA NA >10 signals NA NA 
 
16 
Williamson 
et al, 2016° 71 M 8 pT3aNxMx NA NA NA NA NA >10 signals NA NA 
 
17 
Williamson 
et al, 2016° 28 F 6.5 pT3aN1Mx NA  + NA NA NA >10 signals NA NA 
 
18 
Williamson 
et al, 2016° 61 F 5.3 pT3aNxMx NA NA NA NA NA >10 signals NA NA 
 
19 
Williamson 
et al, 2016° 59 M 4.5 pT1bNxMx NA NA NA NA NA >10 signals NA NA 
 
20 
Gupta et al, 
2017 34 M 9 pT3cNxM1 3 NA NA neg  + >10 signals 
>10 
signals 
dead 
after 21 
months 
soft tissue 
metastasis 
21 
Gupta et al, 
2017 80 M 1.8 pT1aNxM0 3 NA NA neg neg >10 signals 
>10 
signals 
dead 
after 47 
months 
 
22 
Gupta et al, 
2017 65 F 9.5 pT3aNxM0 3 NA NA neg neg >10 signals 
>10 
signals 
dead 
after 73 
months 
soft tissue 
metastasis 
23 
Gupta et al, 
2017 69 F 2.5 pT1aNxM0 2 NA NA neg  + >10 signals 
>10 
signals 
265 
months 
alive 
 
24 
Gupta et al, 
2017 78 M 5.5 pT3cNxM0 3 NA NA neg  + >10 signals 
>10 
signals 
dead 
after 
254 
months 
 
25 
Gupta et al, 
2017 62 M 13 pT2bNxM0 2 NA NA  +  + >10 signals 
>10 
signals 
dead 
after 
194 
months 
 
26 
Gupta et al, 
2017 70 M 10 pT2aN1M0 4 NA NA neg  + >10 signals 
>10 
signals 
dead 
after 18 
months 
bone and 
lung 
metastasis 
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27 
Gupta et al, 
2017 83 M 6.5 pT3cNxM1 4 NA NA neg  + >10 signals 
>10 
signals 
dead 
after 40 
months 
brain, 
lung, 
adrenal 
gland and 
lymph 
nodes  
28 
Gupta et al, 
2017 56 M 13 pT3aNxM0 4 NA NA neg neg >10 signals 
5 
signals 
dead 
after 
242 
months 
 
29 
Gupta et al, 
2017 73 M 3.7 pT3aNxMx 3  +  + NA NA >10 signals NA NA 
 
30 
Gupta et al, 
2017 68 F 18.5 pT3cN0Mx 3 NA NA neg  + >10 signals 
>10 
signals 
dead 
after 18 
months 
bone and 
soft tissue 
metastasis 
31 
Skala et al, 
2017 68 F 6.5 pT3aNxMx 3 NA  + NA  + >10 signals NA NA 
 
32 
Skala et al, 
2017 65 M 5.5 pT3aNxMx 3 NA  + NA NA >10 signals NA NA 
 
33 
Skala et al, 
2017 48 F 10.1 pT2bNxMx 4 NA NA NA  + >10 signals NA NA 
 
34 
Skala et al, 
2017 68 M 12.2 pT4N1M1 4  + NA neg  + >10 signals NA NA 
 
35 
Skala et al, 
2017 72 M 7 pT3aNxMx 3  + NA NA  + >10 signals NA NA 
 
36 
Skala et al, 
2017 69 M 5.9 pT3aN1Mx 3 NA NA NA  + >10 signals NA NA 
 
37 
Mendel 
et.al, 2017 55 F 8 pT2aN0M0 4 NA neg neg neg >20 signals 
NA 
(array 
CGH) 
161 
moths 
alive 
lung 
metastasis 
38 
Mendel 
et.al, 2017 55 F 17 pT4NxM1 4 NA neg neg neg 4-10 signals 
NA 
(array 
CGH) 
dead 
after 1 
month 
renal vein 
thrombus, 
brain 
metastasis 
39 
Mendel 
et.al, 2017 60 M 14 pT3cN0M1 4 NA neg neg 
 + 
(40%) 10-20 signals 
NA 
(array 
CGH) 
dead 
after 14 
months 
renal vein 
thrombus, 
liver 
metastasis 
40 
Present 
series (case 
30) 69 M 7 pT2aNxMx 3  + (30%)  + (40%) neg 
 + 
(90%) 
break + >10 
signals 
> 10 
signals 
14 
months 
alive 
perinephric 
nodules 
after 5 
months 
41 
Present 
series (case 
31) 41 F 3 pT1aNxMx 
2  + (50%) 
 + 
(100%) 
 + (1%)  + (5%) >10 signals 
> 10 
signals 
(10% of 
nuclei)   
6 
signals 
(90% of 
nuclei) 
20 
months 
alive 
 
42 
Present 
series (case 
32) 79 M 10 pT2aNxMx 
3  + (50%)  + (10%) neg neg >10 signals 
> 10 
signals 
(80% of 
nuclei)  
6 
signals 
(20% of 
nuclei) 
18 
months 
alive 
 
NA: not available, * no additional information, ° cases from TCGA  
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